Is a late period a listed side effect of Mounjaro?

No. The Mounjaro and Zepbound labels, both revised in August 2026, list no menstrual adverse reaction in the clinical trial data or the postmarketing reports. A late period on Mounjaro is more likely linked to weight loss, low food intake, or pregnancy.

Can Mounjaro cause spotting between periods?

A 2026 analysis of FDA adverse event reports found more reports of bleeding between periods and menstrual clots with tirzepatide than expected. Such reports cannot prove the drug was the cause. Spotting between periods meets ACOG's definition of abnormal uterine bleeding, so tell a clinician about it.

Will my periods return to normal after I stop Mounjaro?

No study has followed menstrual cycles after people stop tirzepatide, so there is no direct answer. Cycle changes tied to weight loss usually follow body weight and food intake. If periods stay irregular for 3 to 6 months, ACOG's guidance is to have it checked.

Does Zepbound affect periods differently from Mounjaro?

No difference is expected. Zepbound and Mounjaro contain the same drug, tirzepatide, at the same doses, and neither label lists a menstrual side effect. Adverse event studies analyze tirzepatide as one drug.

Can Mounjaro cause bleeding after menopause?

One 2026 analysis of FDA adverse event reports flagged postmenopausal bleeding as a new signal for tirzepatide, with 46 reports. That does not show the drug caused the bleeding. Any bleeding after menopause needs a medical evaluation, whatever medicine you take.

Can Mounjaro Affect Your Menstrual Period?

The short answer: possibly, but the evidence is indirect. The FDA labels for Mounjaro and Zepbound list no menstrual side effect of any kind. Reports to the FDA's adverse event database do show more period changes than expected with tirzepatide, mainly bleeding between periods and clots, but those reports cannot prove cause. The best-supported explanation is weight loss itself, which can make periods more regular in some women and less regular in others.

What does the Mounjaro label say about periods?

Nothing. The current Mounjaro prescribing information (revised August 2026) does not contain the words menstrual, menstruation, or period-related bleeding anywhere in its adverse reactions sections. The same is true of the Zepbound label, which covers the same drug, tirzepatide, for weight management.

The side effects the labels do list are mostly digestive: nausea, diarrhea, vomiting, constipation, and abdominal pain. The Zepbound label also lists hair loss, and the Mounjaro label lists alopecia under postmarketing reports. No menstrual change appears in either the clinical trial tables or the postmarketing list.

A missing entry does not prove the drug has no effect. The large SURPASS and SURMOUNT trials were built to measure blood sugar and body weight. They did not track cycle length or flow as an outcome, so a mild change could go unrecorded.

One line in the label's animal data is relevant. In fertility studies, female rats given tirzepatide had longer cycles (prolonged diestrus) at all dose levels. The label says these effects "were considered secondary to the pharmacological effects of tirzepatide on food consumption and body weight." In other words, the animals' cycles changed because they ate less and lost weight.

What do FDA adverse event reports show?

Three recent analyses used the FDA Adverse Event Reporting System (FAERS). They do not fully agree.

A 2026 analysis of tirzepatide reports from 2022 through early 2025 covered 67,305 cases, 75.83% of them in women. It flagged four menstrual terms as new signals: menstrual disorder (37 reports), polymenorrhea, or frequent periods (17 reports), oligomenorrhea, or infrequent periods (12 reports), and postmenopausal bleeding (46 reports).
A 2026 study in Obstetrics & Gynecology looked only at female patients aged 12 to 55. Tirzepatide produced signals for bleeding between periods and menstrual clots. Semaglutide had a wider set of signals, including heavy bleeding and infrequent periods. Liraglutide had none.
A third 2026 FAERS study adjusted for confounding factors and found the opposite pattern for tirzepatide: lower reporting odds for painful periods, absent periods, and heavy bleeding. Semaglutide again showed more menstrual reports.

FAERS has firm limits. Anyone can file a report, the number of people taking the drug is unknown, and news coverage drives reporting. A signal means a term shows up more often than expected. It does not give a rate, and it does not show the drug caused the event. The first study's author states that it "does not declare explicit risks." The counts are also small: 37 menstrual disorder reports among more than 67,000 cases.

Can weight loss itself change your cycle?

Yes, and in both directions. The U.S. Office on Women's Health says that gaining or losing too much weight can cause missed periods, and that periods usually restart after weight loss in women who are overweight.

Body fat makes estrogen, and excess weight often comes with high insulin levels that disrupt ovulation. When weight and insulin fall, ovulation can return. A woman who had a period every few months may start to have one every month. Bleeding can also be heavier or less predictable for a few cycles while hormone levels shift.

The reverse also happens. An Endocrine Society clinical practice guideline describes functional hypothalamic amenorrhea as a form of chronic anovulation often associated with stress, weight loss, excessive exercise, or a combination of these. Fast weight loss with low food intake can make periods lighter, later, or absent. This matches the rat data in the label.

Tirzepatide causes large weight loss in a short time, so either effect is plausible. Eating enough protein and total calories matters here. Our Mounjaro diet plan covers intake targets, and calories.md explains energy needs in more detail.

Does Mounjaro make periods more regular with PCOS?

Early evidence says it can. Polycystic ovary syndrome (PCOS) is a common cause of infrequent periods, and weight loss is a standard part of treatment.

A 2024 systematic review in Annals of Internal Medicine pooled 29 comparisons with 1,529 participants with PCOS. Weight loss interventions, including GLP-1 drugs, were linked to a statistically significant improvement in menstrual frequency. That finding is for weight loss in general and predates tirzepatide trials in PCOS.

For tirzepatide, the direct evidence is one small trial. A 2026 randomized, open-label trial assigned 60 women with PCOS and overweight or obesity to metformin alone or metformin plus tirzepatide 5 mg once weekly for 16 weeks. The tirzepatide group lost 10.4 kg compared with 1.7 kg, and menstrual cycle recovery was higher (p = 0.013). The trial was short, unblinded, and done at one center in China. Mounjaro is not FDA-approved for PCOS. Our Mounjaro and PCOS article covers that topic in full.

Could a missed period on Mounjaro mean pregnancy?

Yes. Take a pregnancy test before you assume the drug or the weight loss is the cause. There are two reasons pregnancy is more likely on tirzepatide than many people expect.

Ovulation can return. Women who rarely ovulated before may start to ovulate as weight falls.
Birth control pills may work less well. The Mounjaro label says tirzepatide "may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying." It advises a non-oral method or an added barrier method for 4 weeks after starting and for 4 weeks after each dose increase.

Spotting can also be a pill effect. If pill hormones absorb poorly, breakthrough bleeding is possible, although no study has measured this with tirzepatide. Our article on Mounjaro and birth control gives the label's numbers and the unaffected methods.

The labels are cautious about pregnancy. The Mounjaro label says human data are insufficient and animal studies suggest possible risk to the fetus. The Zepbound label says to discontinue the drug when a pregnancy is recognized. Call your prescriber promptly after a positive test.

When should you call your doctor about period changes?

A cycle that shifts by a few days during weight loss is usually not a concern. The American College of Obstetricians and Gynecologists (ACOG) defines abnormal uterine bleeding with a specific list. Contact a clinician if you have any of these:

Bleeding or spotting between periods, or after sex
Bleeding that soaks through one or more pads or tampons every hour
Bleeding that lasts more than 7 days
Cycles longer than 35 days or shorter than 21 days
No period for 3 to 6 months
Any bleeding after menopause

Bleeding after menopause always needs an evaluation, on Mounjaro or not. ACOG also advises emergency care if you change pads or tampons every hour for more than 2 hours and have chest pain, shortness of breath, or dizziness.

Keep a simple record of start dates, length, and flow, along with your dose and weight. It helps a clinician tell a weight-loss pattern from thyroid disease, fibroids, PCOS, or perimenopause. Do not stop or change your Mounjaro dose on your own because of a cycle change.

The bottom line

Mounjaro can coincide with period changes, but no label lists one and no trial has measured it as a drug effect. Adverse event reports show a weak and inconsistent signal. Weight loss explains most of what is known: periods often become more regular in women with PCOS or obesity, and can become lighter or stop with fast loss and low intake. Rule out pregnancy after a missed period, use backup contraception as the label directs if you take the pill, and report bleeding that fits ACOG's abnormal list.

Last updated: October 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your prescriber or gynecologist about any change in your menstrual cycle while taking Mounjaro.